In BL, high level of MYC and founder alterations induce a field defect characterized by the aberrant activation of PI3K signaling pathway and other changes mediated by the non-canonical binding of MYC to other proteins and genetic loci [29, 53, 54]. The gene discussed is MYC; the disease is Burkitt lymphoma.